Evogene Plunges 11.02% on ICL Acquisition, Q4 Earnings

On April 22, 2025, Evogene's stock price dropped by 11.02% in pre-market trading.

Evogene, a computational biology company, focuses on revolutionizing product development for life-science based industries, including human health, agriculture, and industrial applications. The company's Computational Predictive Biology (CPB) platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements.

Recently, ICL announced its acquisition of the activities of Evogene's subsidiary, Lavie Bio. Lavie Bio is known for its improvements in agriculture, which could potentially impact Evogene's future revenue streams and market position.

Evogene reported its fourth quarter and full year 2024 financial results, which showed a latest annual turnover of USD 8.51M and an annual profit of USD -16.49M. The company's financial performance is a key factor that investors consider when evaluating the stock's potential.